Cardiothoracic & vascular anesthesia
Magnesium Sulfate to Prevent Perioperative Atrial Fibrillation in Cardiac Surgery: A Randomized Clinical Trial
Primary result · POAFResult — go to the resultRelative risk 1.29 95% CI 0.92–1.80Authors' conclusion
In this randomized trial, perioperative magnesium infusion targeting serum concentrations of 1.5-2.0 mmol/L did not reduce POAF after cardiac surgery.
Study context
- Population
- Adults undergoing CABG and/or valvular surgery without prior atrial arrhythmias or severe renal dysfunction, single centre, The Netherlands, February 2022-November 2023stopped for futility
- Participants
- 265 adults
- Comparison
- Perioperative IV magnesium sulfate infusion vs placebo
- Magnesiumn = 132
- Placebon = 133reference
Methodological detailsdouble-blind, placebo-controlled, single-centre, interim analysis for futility
- Double-blind
- Placebo-controlled
- Single-centre
- Interim analysis for futility
Primary result
POAF
Relative risk
1.29
95% CI 0.92–1.80
Events by treatment group
Magnesium vs Placebo
RR 1.29 (95% CI 0.92–1.80)
As reported in the abstract
Further findings
Serum magnesium concentrations
- Clear separation in serum magnesium concentrations between groups
Postoperative atrial fibrillation (POAF) by subgroup (subgroup)
- No subgroup demonstrated benefit
Time-to-event and day-by-day POAF
- No early reduction in POAF with magnesium
Vasopressor use
- More frequent in the magnesium group, differences not statistically significant
Safety
- No safety signal identified
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Magnesium Sulfate to Prevent Perioperative Atrial Fibrillation in Cardiac Surgery: A Randomized Clinical Trial. Crit Care Med. Published 28 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →